VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2021 | Systemic versus intravesical therapy for NMIBC

Arjun Balar, MD, NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses systemic treatment versus intravesical treatment of patients with non-muscle-invasive bladder cancer (NMIBC). Dr Balar outlines the benefits of using systemic therapies such as PD-1 targeting antibodies, and highlights increased reliability of systemic immunotherapies versus intravesical approaches. This interview took place during the 2021 Genitourinary Cancers Symposium.

Disclosures

Dr Arjun Balar, MD, has received consultancy fees from Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics and Immunomedics; has received fees for contracted research from Genentech, Merck, AstraZeneca/Medimmune, Nektar, Seattle Genetics and Immunomedics; has participated in speaking engagements for Genentech, Merck and AstraZeneca/Medimmune; has participated in steering committees with Merck and Nektar; and has equity and is a member of the scientific advisory board of EpiVax Oncology.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter